E-Tech Resources Inc. (“E-Tech” or the “Company”) (TSXV:REE) (FSE:K2i) announces the approval of its new Deferred Share Unit Plan (“DSU Plan”), which complies with Policy 4.4 of the TSX Venture Exchange. The DSU Plan was first approved by the Company’s shareholders at its 2023 Annual and Special Meeting and was reapproved by shareholders at the Company’s Annual and Special Meeting held on September 26, 2024. The DSU Plan is administered by the Company’s Compensation Committee, and any DSUs issued to qualified participants will vest at a rate of one-third on each anniversary date of the DSU grant. For further information on the DSU Plan, refer to the Company’s Management Information Circular dated August 22, 2024.
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has granted 2,135,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) of which 1,855,0000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company’s Stock Option Plan.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce plans to advance its 100% owned gold projects in Saskatchewan, Canada (the “Goldfields Project”) and Chiapas, Mexico (the “Ixhuatán Project”). The plans, highlighted below, are designed to materially advance the projects, demonstrate their intrinsic value and deliver key value drivers for the Company as it embarks on the process of unlocking value for these two significant gold assets.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce that it has closed its non-brokered private placement (the “Offering”), previously announced on April 7, 2025, for aggregate gross proceeds of $3,000,000. The Company issued 9,375,000 units. Each unit was issued at a price of $0.32 per unit, with each unit comprised of one common share and one-half common share purchase warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of $0.45 per share for the first year from the date of issuance and $0.55 per share for the second year from the date of issuance. Directors, officers and other non-arm’s length parties of the Company subscribed for an aggregate of 1,531,250 units.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce that it intends to increase the non-brokered private placement (the “Offering”), previously announced on April 2, 2025, to aggregate gross proceeds of up to $3,000,000. The Company intends to issue up to 9,375,000 units. Each unit will be issued at a price of $0.32 per unit, with each unit comprised of one common share and one-half common share purchase warrant. Each whole warrant will be exercisable into one common share of the Company at an exercise price of $0.45 per share for the first year from the date of issuance and $0.55 per share for the second year from the date of issuance.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement for aggregate gross proceeds of up to $2,800,000 (the “Offering”). The Company intends to issue up to 8,750,000 units. Each unit will be issued at a price of $0.32 per unit, with each unit comprised of one common share and one-half common share purchase warrant. Each whole warrant will be exercisable into one common share of the Company at an exercise price of $0.45 per share for the first year from the date of issuance and $0.55 per share for the second year from the date of issuance.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce the commencement of drilling at Howland Lake on the Murmac Uranium Project (“Murmac” or the “Project”), located in northern Saskatchewan near Uranium City.
The program is expected to include up to six drill holes, totalling approximately 900 metres, to further test the Howland Lake electromagnetic (“EM”) conductors which returned uranium intercepts from first-pass drilling. As demonstrated from previous exploration results, the Project has potential to host high-grade, basement-hosted deposits typical of the Athabasca Basin.
Halifax, Nova Scotia – (Newsfile Corp. – March 19, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to provide updated data confirming efficacy of its Targeted Hyperthermia Therapy (“THT”) cancer treatment in an immunotherapy resistant cancer. In this follow-up data to the previously released preliminary study (see press release dated December 11, 2024), again using an industry-standard, immunotherapy resistant, CT-26 colon cancer model, Sona’s THT cancer treatment was 100% effective in activating a strong, effective immune system response. In these experiments, animals treated with a PD-1 checkpoint inhibitor, a standard of care immunotherapy, experienced no benefit with tumors growing similarly to tumors in the control group of untreated animals. However, in a new, second cohort of eight animals first treated with Sona’s THT and then treated with a PD-1 inhibitor, 100% of animals responded demonstrating near complete arrest in tumor growth in the majority of animals as highlighted by the dashed green line in Figure 1, below.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce winter drill targets for the Murmac Uranium Project (“Murmac” or the “Project”), located in northern Saskatchewan near Uranium City. The drill targets are supported by the recent completion of a radon-in-water survey at Howland Lake which produced strong anomalies along strike of the high-grade uranium drill intersections obtained during summer 2024. A winter drilling program, to test these targets, is expected to commence in March 2025.
Halifax, Nova Scotia – (Newsfile Corp. – February 12, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that recently published findings from its “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” study will be presented at the International 19th Canadian Melanoma Conference on February 20th in Vancouver. Sona’s Chief Medical Officer, Dr. Carman Giacomantonio, a planning committee member for this conference, and Dr. Barry Kennedy, of The Giacomantonio Immuno-Oncology Research Group, will present both poster and oral presentations.